Zealand Pharma obesity drug continues to phase II

Dapiglutide demonstrated weight loss of up to 4.3% of baseline body weight after four weeks of treatment.

Photo: Zealand Pharma / PR

Novo Nordisk and Eli Lilly are battling it out on the billion-dollar obesity market, and Zealand Pharma wants in.

The biotech company, which is based in Denmark, has released phase I data on its GLP-1/GLP-2 dual agonist dapiglutide within the obesity indication, and announced that a phase II trial will now be initiated.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs